Artes and Rhein Minapharm Produce New Therapeutic Protein Target
Artes Biotechnology (Langenfeld, Germany) and Rhein Minapharm Biogenetics (Cairo, Egypt) have produced a new target of a therapeutic protein.
Artes Biotechnology (Langenfeld, Germany) and Rhein Minapharm Biogenetics (Cairo, Egypt) have produced a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies have extended their collaboration through May 2009.
Artes applied its proprietary Hansenula technology platform to the generation of a therapeutic protein chosen by Rhein Minapharm that is typically produced in E coli. Rhein Minapharms’s new target is now produced from the Hansenula polymorpha platform at considerable higher yields and at reduced costs, compared to alternative bacterial or yeast systems. Because of these advantages, a number of products marketed worldwide—such as the hepatitis B vaccine, insulin, interferon, hirudin, and several feed and food enzymes—are now manufactured with the Hansenula technology. Several others also are in clinical trials in Europe and the US.
Under the terms of agreement, Artes handed over the production cell lines and received another milestone payment. Additionally, Artes and Rhein Minapharm extended their collaboration, now aiming at additional targets for Minapharm’s portfolio. Artes will be responsible for the generation of new production cell lines and will share the process research and development responsibility with Minapharm.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
